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INTRODUCTION
Modification of histones by acetylation, in addition to other epigenetic processes, can play a key role in tumorigenesis (1) . Histone deacetylase (HDAC) enzyme can affect chromatin condensation by deacetylating the lysine residues of histones that restrict access to transcriptional sites, and thus regulate gene expression. Aberrant activity of HDACs has been documented in a variety of cancers and HDACs have emerged as an attractive therapeutic target (2) . HDAC inhibitors (HDACi) are a structurally diverse group of anti-cancer agents which can cause changes in gene expression, induction of apoptosis, cell cycle arrest and differentiation, by altering the acetylation status of histone and non-histone proteins.
Additionally, HDACi result in degradation of proto-oncogenes, including the epidermal growth factor receptor and human epidermal growth factor receptor 2/neu by acetylating the molecular chaperone heat shock protein 90 (HSP90) and can also play a role in inhibiting angiogenesis (3) (4) . HDACi have pleiotropic effects on malignant cells and have demonstrated potent anti-cancer activity in pre-clinical studies. Despite the promising preclinical activity, only two HDACi namely vorinostat (suberoylanilide hydroxamic acid) and romidepsin (depsipeptide) have been approved by the US FDA for treatment in selected cases of cutaneous T-cell lymphoma (5) (6) .
Quisinostat is a novel hydroxamate based HDACi which exerts broad spectrum antiproliferative activity against a wide panel of cancer cell lines including lung, colon, breast, prostate and ovarian cell lines at nanomolar concentrations. Quisinostat inhibits both class I and II HDACs and has demonstrated sustained H3 acetylation and potent antitumor activity in preclinical in vivo models of human cancers (7) . In addition, quisinostat exhibits potent antitumor activity in murine models of multiple myeloma, with near complete 6 reduction in tumor load and significant decrease in angiogenesis (8) . Quisinostat has been demonstrated to have excellent tissue distribution properties in preclinical studies (9) .
Here, we report results of a first-in-human, phase I study in patients with advanced malignancies that determined dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of quisinostat and evaluated its safety and pharmacokinetic properties in patients with advanced stage or refractory solid malignancies and lymphoma. Also evaluated were the effect of food on pharmacokinetics of quisinostat, antitumor activity and pharmacodynamic effects in tumor and surrogate tissues.
PATIENTS AND METHODS

Study population
Eligible patients were those ≥18 years of age with advanced solid tumors or lymphomas that were refractory to standard therapy, with Eastern Cooperative Oncology Group (ECOG) performance status score ≤2, life expectancy >3 months and adequate gastrointestinal, hepatic, renal, bone marrow, and cardiac function. Patients at increased cardiac risk were excluded, including those with uncontrolled hypertension, unstable angina, myocardial infarction within the previous 12 months, left ventricular ejection fraction (LVEF) <50%; congestive heart failure of New York Heart Association (NYHA) (10) Class II-IV; any history of cardiomyopathy or ventricular arrhythmia; requirement for a cardiac pacemaker; or a family history of long QT syndrome. Patients were not allowed to take concomitant medications known to have a risk of causing QTc prolongation and torsades de pointes. Other exclusion criteria included: brain metastases; chemotherapy (in case of nitrosoureas or mitomycin C within 6 weeks) or radiotherapy or immunotherapy within 4 weeks before study drug administration; grade ≥2 neuropathy; or positive serology for hepatitis B, hepatitis C or human immunodeficiency virus. Women who were pregnant, planning to become pregnant or were nursing, were excluded. Patients previously treated with HDACi were also excluded.
An Independent Ethics Committee at each study site approved the protocol. This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in accordance with ICH Good Clinical Practices guidelines, applicable regulatory requirements, and in compliance with the protocol. All patients provided written informed consent to participate in the study before undergoing any study-related procedures. A Data Review Committee (DRC) was formed to ensure optimum study conduct.
Study design
This phase I dose escalation study was conducted from September 2007 to September 2011 at 5 study centres in the United Kingdom, in an outpatient setting. It included a 14-day screening phase, an open-label phase consisting of 21-day treatment cycles of quisinostat, and an end-of-study visit within 14 days after the last dose. The study was divided into two parts, a dose-escalation phase (Part 1) and an expansion phase (Part 2). The study drug was administered orally, once-daily, starting with 2 mg/day dose with continuous treatment schedule. Cycle 1 was designated as the DLT period; DLT was defined as either treatment interruption of >7 days for grade ≥2 toxicity during the 21-day cycle, grade 3 or grade 4 nonhematological toxicity (excluding nausea or vomiting responsive to antiemetic treatment, alopecia, clinically tolerable diarrhea responding to antidiarrheal treatment, isolated grade 3 gamma-glutamyl transpeptidase elevations, grade 3 fatigue, grade 3 asthenia, and grade 3 troponin I rise in the absence of other evidence of myocardial damage indices), grade ≥3 nausea or vomiting despite adequate anti-emetic treatment, persistent grade ≥2 nausea or vomiting despite anti-emetic treatment for >7 days, grade ≥3 diarrhea despite adequate anti- MTD was defined as the highest dose at which <2 out of 6 patients experienced a DLT.
During Part I of the study, a Korn's two-stage accelerated titration design (11) was followed to minimize the number of patients exposed to sub-therapeutic doses of quisinostat. Initially, 2 patients were included in each cohort and 100% dose increments were applied. Following the first event of a drug-related grade ≥2 toxicity (except grade 2 fatigue, asthenia, anorexia and nausea, vomiting and diarrhea, if adequately treated within 7 days) subsequent treatment followed a conventional 3+3 dose escalation design with up to 3 additional patients added if one patient exhibited a DLT. Further dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT. Dose escalation decisions were based on the safety and pharmacokinetic data from cycle 1.
During part 2, additional patients were enrolled for safety, pharmacokinetics, antitumor activity, and pharmacodynamics assessments. In this phase, patients were treated at the MTD level and 19 patients were enrolled at 12mg dosing on MWF schedule.
Intrapatient dose escalations were not allowed anytime during the study. Patients were discontinued from the study in the event of progressive disease (PD) or any unacceptable toxicity.
During cycle 1, pharmacokinetic, pharmacodynamic and toxicity assessments were carried out on days - The study drug, quisinostat (Jansssen Research and Development, LLC) was supplied as capsules for oral use, in strengths of 1, 5 and 20 mg. The study drug was administered within 5 minutes after breakfast and patients fasted at least for 2 hours after taking the study drug.
Continuous treatment schedule (starting with 2 mg/day dose) and intermittent treatment schedules, Monday/Wednesday/Friday (MWF), 4 days on/3 days off (starting with 6 mg/day dose), and Monday-Thursday (M-Th; starting with 8 mg/day dose) were evaluated in this study. The MTD was determined for all treatment schedules.
Safety evaluations
Safety assessments included monitoring for treatment-emergent adverse events (TEAEs), DLTs, clinical laboratory tests, vital signs, physical examinations, and 12-lead electrocardiograms (ECG), and 24-hour Holter monitoring. Ejection fraction was assessed by either echocardiograms or MUGA (multigated acquisition) scans at baseline and the end of cycle 2. Adverse events were evaluated in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (12), and were followed to a satisfactory resolution or a clinically stable endpoint.
Research. Belgium. The method is based on a protein precipitation extraction followed by liquid chromatography coupled to ion-spray tandem mass spectrometry in the positive ion mode.
The method has a lower limit of quantitation of 0.1 ng/mL plasma.
Pharmacokinetic parameters
Non-compartmental analysis was performed using WinNonlin (Pharsight Corporation, 
Histone acetylation
Blood samples collected in sodium citrate tubes (BD Vacutainer™) were spun immediately at room temperature to separate plasma and PBMC. PBMCs were washed twice with phosphate buffered saline (also at room temperature), then snap frozen in dry ice and stored at -80 o C until further analysis.
AcH3 in PBMCs was measured by ELISA using MSD platform with Ruthenium labelled goat anti-rabbit IgG (detection antibody, MSD), Mouse pan anti-histone monoclonal antibody (coating antibody, Millipore) and rabbit AcH3 polyclonal antibody (Millipore). The lower cut off was defined as 0.0048 ng/ug protein based on the assay variability of the standard curve which was generated using an acetylated H3 peptide (Millipore).
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on AcH3 in skin and tumor biopsies from formalin-fixed paraffin-embedded blocks was detected in sections stained on a DAKO autostainer, which were deparaffinised and rehydrated for antigen retrieval by heat-induced antigen retrieval process in citrate buffer at pH 6 and 95 0 C for 30 minutes. Endogenous peroxidases were blocked with H 2 O 2 . Sections were incubated with primary antibody anti-histone 3 (Millipore) followed by peroxidase labelled secondary antibody (Dako Envision system HRP labelled polymer antimouse). Protein antibody complexes were visualised using 3,3-diaminobenzidine (DAB) (Dako liquid DAB + substrate chromogen system). Haematoxylin was used for nuclear staining.
AcH3 in hair follicles were assessed by harvesting 3-4 hair follicles with intact bulb, which was fixed in 10% formalin saline at 4 0 C. Antigen was retrieved at 95 0 C for 15 minutes with and FITC and Cy5 images were captured by confocal microscope (Leica Microsytems, Germany). The change in AcH3 was expressed as fold change (based on intensities of acetylated histone nuclear stain) between mean pre-treatment and post treatment staining.
Ki67 analysis
Ki67 was stained in skin and tumor biopsies as per IHC method for AcH3 estimation. Ki67
clone MIB-1 ready-to-use mouse monoclonal antibody (Dako) was used.
on 
Efficacy evaluations
Baseline tumor assessments were performed by CT or MRI within 4 weeks of starting study treatment and efficacy was evaluated by repeat imaging and tumor markers (if appropriate) after every 2 treatment cycles until 8 cycles following which the imaging schedule was at investigators' discretion. The tumor assessments were performed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (13) for solid tumors and the International Working Group Standardized Response Criteria (IWGSRC) (14) for lymphoma.
Statistical analysis
The pharmacokinetic and pharmacodynamic analysis sets included patients who had sufficient and interpretable data for treatment with quisinostat. The safety analysis set included all patients who received at least one dose of quisinostat. Descriptive statistics were used to summarize the pharmacokinetic, pharmacodynamic, safety and efficacy results.
RESULTS
Patient disposition and baseline characteristics
A total of 92 patients were enrolled in the study of which 52% were women. The median age of patients was 56 years (Table 1) reasons for treatment discontinuations were disease progression (n=73, 79.3%), adverse events (n=12, 13%), withdrawal of consent (n=2, 2.2%), death (n=1, 1.1%) and other reasons (n=4, 4.3%).
Safety Dose escalation, DLTs and determination of MTD
Ten (11%) patients experienced DLTs during the study (Table 2) , which were predominantly cardiovascular. The MTD of quisinostat was found to be 8 mg with continuous treatment, 10 mg with 4 days on / 3 days off treatment, 12 mg with MWF treatment and 15 mg with M-Th treatment ( Table 2 ). The MTDs were found to correlate inversely with dose intensity. 
Treatment-emergent adverse events
Eighty-two (89%) patients experienced TEAEs that were considered at least possibly related to study drug; the most frequently reported (occurring in ≥10% of patients) drug-related TEAEs were fatigue, lethargy, nausea, decreased appetite, ventricular tachycardia, vomiting, and cardiac disorders ( Table 3 ). The majority of these TEAEs were mild to moderate in severity. Fatigue or lethargy was the most common side effect reported and was seen in 57.6% of patients, however only in one instance fatigue was the DLT and in general it was less common in the intermittent regimens (Table 3) . Of note, at the recommended dose of 12 mg MWF, grade 3 fatigue/lethargy was seen in 3/26 (12%) patients. Nausea, decreased appetite and vomiting were reported in 32%, 22% and 17% of patients, respectively. There were no grade 3/4 events of nausea and one case of grade 3 vomiting was reported in the entire trial. These symptoms were well controlled by anti-emetics such as domperidone and cyclizine.
Cardiac arrhythmia has been identified as an adverse effect of quisinostat. In 27% of patients, increased ventricular ectopic activity has been observed on serial Holter recordings (Supplemental Table 1 
was associated with palpitations, dizziness and breathlessness requiring discontinuation of study drug. There was no evidence of QTc prolongation based on statistical analysis or based on a pharmacokinetic versus QTc correlation analysis. No effect on left ventricular ejection fraction was observed in patients with serial measurements at baseline and on study drug.
Two patients receiving 8 mg of quisinostat died during the study: one on continuous treatment schedule (pneumonia) and the other on MWF treatment schedule (progressive disease); both events were not considered to be study drug related.
No clinically relevant changes were observed in clinical laboratory values, vital signs, and physical examinations. There were no observations of grade 3/4 neutropenia or grade 3/4 thrombocytopenia.
Pharmacokinetics
Absorption of quisinostat was rapid with t max ranging between 1 and 6 hours across all treatment schedules and doses. Generally, the C max and AUC 0-last values increased roughly proportionally with dose on day 1 (Supplemental Table 2 ) as well as at the steady state (Table 4) Table   2 ). Overall, pharmacokinetics of quisinostat was similar for continuous and intermittent treatment schedules apart from plasma drug exposure which was numerically higher in MWF schedule. The pharmacokinetic profile at the recommended phase II dose achieved drug concentration that was known to be effective in animal models (Supplemental Figure 1) . In the 13 patients where pharmacokinetics was evaluated in fed and fasted state at 6 and 8mg
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once daily dosing to ascertain food effect, no clinically meaningful effect was noted on drug absorption (AUC last fasted/AUC last fed ratio: 1.03). Food intake however appeared to have a marginal effect on the rate of absorption (C max fasted/fed ratio: 0.87).
Pharmacodynamics
Acetylation of Histone 3 and Ki67
Treatment with quisinostat resulted in increased levels of AcH3 in PBMC, skin biopsies and hair follicles at all evaluated doses in the intermittent treatment schedules. In PBMCs, the greatest change from baseline levels varied between 35% and 548% in individual samples and mean increase per dose level ranged between 126% and 331% ( Figure 1A ). There was evidence of an increase in levels of AcH3 measured in hair follicles following treatment with quisinostat ( Figure 1B ) and there was a trend towards dose dependent increase in histone 3 acetylation, starting at 6 mg dose level, (R 2 =0.323) ( Figure 1C ). In skin biopsies, proliferation index (% Ki67 labeled nuclei) generally decreased after the treatment (data not shown). Three matched pre and post tumor biopsies were performed and it was possible to show changes in pharmacodynamic biomarkers in all 3 paired samples ( Figure 1C ).
Efficacy
There was one confirmed partial response observed in the study (Figure 2A 
Recommendation of phase II dose
The dose of 12 mg given 3 times a week (MWF) was chosen as the recommended phase II dose. The factors that were taken into consideration were toxicity, PK and PD. There were no Overall, the safety profile of quisinostat in the present study was similar to other HDACi which are in clinical development or approved for the treatment of cancer patients. Previously reported HDACi toxicities include: fatigue, asthenia, nausea, vomiting, diarrhea, cardiac toxicities and hematologic toxicity (predominantly thrombocytopenia) (4) . Cardiac toxicities in particular, conduction abnormalities and rhythm disturbances ranging from non-specific T wave and ST segment changes to ventricular tachycardia have been well documented with a number of other HDACi (4, (15) (16) (17) . A phase II study of depsipeptide in patients with neuroendocrine tumors was terminated to due to sudden death related to ventricular arrhythmia (18) . In a previous study with romidepsin, two patients experienced drug-related asymptomatic ventricular tachycardia (19) . The phase II study of romidepsin in cutaneous T cell lymphoma patients, revealed ST segment changes and T-wave flattening in nearly twothirds of patients and ventricular/supraventricular tachycardia in 34% of patients but without any deaths (20) . Atrial fibrillation and prolonged QTc interval have also been associated with belinostat (16) and QT prolongation is a class effect of HDACi (21) . In this study, extensive cardiac monitoring was incorporated and cardiologist's advice was sought wherever appropriate. There were no treatment-related deaths. Dose limiting non-sustained ventricular tachycardia which resolved after treatment discontinuation was noted in 3 patients on 8 and 
schedule. Similarly, the proliferation index, assayed by Ki67 staining was reduced in patients treated with quisinostat whose tumors and surrogate tissues were evaluable.
Treatment with quisinostat resulted in disease control (partial response or stable disease) in 9 (9.8%) patients who were heavily pre-treated. Continuous daily dosing was associated with antitumor activity (Figure 2) as evidenced in patients with melanoma but was associated with significant toxicity. Therefore, in addition to the continuous treatment schedule, alternative schedules of administration were evaluated in this phase 1 study.
Based on safety, efficacy, pharmacokinetic, and pharmacodynamic results, the recommended dose of quisinostat for phase II trials is 12 mg on the MWF treatment schedule.
Preclinical studies of quisinostat has shown activity in variety of cell line models including lung, breast, ovarian and prostate cancer (7) in addition to haematological malignancies such as myeloma (22) . However the only previous indication where HDAC inhibitors have been licensed is CTCL and a study of quisinostat for the treatment of CTCL revealed significant anticancer activity (23) .
CONCLUSION
Quisinostat was well tolerated and showed promising antitumor activity in patients with advanced solid tumors, in particular melanoma. The favorable pharmacokinetic and pharmacodynamic properties and acceptable safety profile of quisinostat observed in this study warrants further development of quisinostat as a monotherapy or in combination with other anticancer agents with synergistic activity and non-overlapping toxicity. The 12 mg dose given three times weekly (MWF) is recommended for phase II development. 
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